This article is more than 5 years old. Information may no longer be current.

AnaptysBio secures funding for pustular psoriasis, asthma, peanut allergy studies

AnaptysBio has secured $40 million Series D financing for antibody research in pustular psoriasis and adults with asthma and peanut allergies, according to a press release.

“The proceeds of this financing provide AnaptysBio with the financial strength to potentially demonstrate efficacy in our anti-[interleukin (IL)]-33 program in severe adult asthma and peanut allergy patients, while also advancing our anti-IL-36 receptor program to proof-of-concept in generalized pustular psoriasis,” Hamza Suria, president and CEO of AnaptysBio, said in the release.

BioMed Ventures, Comcorant Asset Management, Frazier Healthcare, HBM Healthcare Investments, Longwood Capital Partners, Nova A/S and additional undisclosed inventors participated in the oversubscribed $40 million Series D financing round, the release stated.

Proceeds from the financing are intended to be used toward AnaptysBio’s first-in-class antibody programs in phase 2 studies, according to the release.

“The financing also will support the continued discovery of novel therapeutic antibodies against emerging target biology in inflammation and immuno-oncology using AnaptysBio’s proprietary somatic hypermutation-based antibody discovery program,” the release stated.

Reference: www.anaptysbio.com